Gastrointestinal Cancer

Findings from a phase 2 trial indicate that CTX-009 plus paclitaxel may produce an encouraging responses in patients with advanced biliary tract cancer, according to investigators.

Patients with advanced biliary tract cancer experience modest clinical benefit following treatment with atezolizumab and cisplatin/gemcitabine with or without bevacizumab.

Patients with newly diagnosed, advanced biliary tract cancers do not have a statistically significant survival benefit following treatment with nab-paclitaxel plus gemcitabine and cisplatin.

Patients with previously untreated advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma continue to benefit from treatment with nivolumab and chemotherapy.

Long-term survival benefit is seen in patients with treatment-naïve advanced esophageal squamous cell carcinoma who were treated with nivolumab plus chemotherapy or ipilimumab.

Investigators report benefit in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with first-line zolbetuximab and mFOLFOX6.

HER-Vaxx with standard-of-care chemotherapy yielded benefit in patients with HER2-overexpressing metastatic or advanced gastric/gastroesophaeal junction adenocarcinoma.

Findings from the phase 3 INTRIGUE trial highlighted improved median progression-free survival in patients with KIT exon–mutated gastrointestinal stromal tumors compared with sunitinib.

Positive topline data from the phase 2b HERIZON-BTC-01 trial indicate zanidatamab may improve outcomes for patients with HER2-amplified and expressing biliary tract cancers.

Patients with gastroenteropancreatic neuroendocrine tumors may benefit from treatment with radionucleotide therapeutic 177Lu-edotreotide, which received fast track designation from the FDA.

Results from a randomized controlled trial highlighted that the TissueCypher Barrett’s Esophagus Test heightened accuracy for assessing progression risk in high-grade dysplasia and esophageal adenocarcinoma among patients with Barrett’s esophagus.

Results from the phase 2 IMMUCHEC trial indicated that tremelimumab with or without durvalumab did not meet the primary end point of improved objective response rate vs chemotherapy in patients with treatment-naïve biliary tract cancer.

The FDA has granted orphan drug designation to second-line GNS561 following the completion of a phase 1/2a trial evaluating the novel PPT1 inhibitor in liver cancer and cholangiocarcinoma.

Findings from the phase 1/2 ReFocus study highlighted that RLY-4008 is a potentially transformative agent for the treatment of FGFR inhibitor–naïve, FGFR-mutant cholangiocarcinoma.

Long-term follow-up of the phase 2 DESTINY-Gastric02 study revealed fam-trastuzumab deruxtecan-nxki continues to show promise in locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Patients with locally advanced or metastatic biliary tract cancer can now receive treatment with durvalumab plus gemcitabine following the combination’s approval by the FDA.

“...we don’t focus on survivorship enough. It’s important to understand the other factors involved in surviving besides just a treatment.”

Patients with ERBB2-positive esophagogastric adenocarcinoma appeared to experience improved efficacy following treatment with a combination of trastuzumab and nivolumab plus leucovorin, fluorouracil, and oxaliplatin vs historical data.

Stacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.

The FDA has delayed the decision to approve tislelizumab monotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma following prior systemic therapy, due to COVID-19 travel restrictions.

In this month's Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, discusses oxaliplatin hypersensitivity reaction in gastrointestinal cancer.

The phase 3 RATIONALE 306 trial showed improved overall survival for patients receiving tislelizumab plus chemotherapy vs placebo and chemotherapy for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 status.

Results from the phase 2 HERIZON study identified improved overall survival for patients treated with IMU-131 plus standard of care vs standard of care alone in advanced or metastatic gastric or gastroesophageal junction cancer.

Patients with gastrointestinal stromal tumors may benefit from 68GA-RM26 PET/CT vs 18F-FDG, according to findings presented at the 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting.

A 100% clinical complete response rate was observed when patients with stage II/III mismatch repair-deficient locally advanced rectal cancer were treated with dostarlimab.

A Claudin18.2–specific CAR T-cell therapy has shown promise in the treatment of patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma whose disease expresses the marker.

The results of the phase 3 TOPAZ-1 trial led to the priority review of durvalumab plus chemotherapy in patients with locally advanced biliary tract cancer.

Patients with unresectable or metastatic gastric or gastroesophageal junction cancer that is relapsed/refractory following other approved therapies may benefit from treatment with single-agent CMG901, which was granted fast track designation by the FDA.

Patients with resectable gastric and gastroesophageal junction adenocarcinoma experienced good pathologic complete response with standard of care chemotherapy and perioperative/adjuvant pembrolizumab.

Results of CheckMate 649 trial show consistently improved outcomes across advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma when nivolumab is administered in combination with chemotherapy.